Cargando…
T203. RELEVANT CLOZAPINE BLOOD LEVELS USING A POINT OF CARE TEST (POCT)
BACKGROUND: Clozapine is one of the most underused medications in psychiatry for many reasons including mandatory blood testing, fear of serious side-effects, lack of patient adherence. A critical barrier to adoption could be addressed with the ability to measure clozapine at point-of-care (POC) fro...
Autores principales: | Kelly, Deanna, Marie Kearns, Ann, Glassman, Matthew, Atkins, Matthew, McQuire, Philip |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7234527/ http://dx.doi.org/10.1093/schbul/sbaa029.763 |
Ejemplares similares
-
T19. GLUTAMATE AND RESPONSE TO CLOZAPINE IN TREATMENT RESISTANT SCHIZOPHRENIA
por: Egerton, Alice, et al.
Publicado: (2020) -
T44. 12-MONTH FOLLOW UP OF METABOLIC MEASURES FOLLOWING A RANDOMISED CONTROLLED TRIAL OF TREATMENT OF CLOZAPINE ASSOCIATED OBESITY AND DIABETES WITH EXENATIDE (CODEX)
por: Siskind, Dan, et al.
Publicado: (2020) -
T204. CLOZAPINE COMBINATION AND AUGMENTATION STRATEGIES IN PATIENTS WITH SCHIZOPHRENIA –RECOMMENDATIONS FROM AN INTERNATIONAL EXPERT SURVEY AMONG THE TREATMENT RESPONSE AND RESISTANCE IN PSYCHOSIS (TRRIP) WORKING GROUP
por: Wagner, Elias, et al.
Publicado: (2020) -
T192. BINSWANGER’S THREE FORMS OF FAILED EXISTENCE AND ITS RELEVANCE FOR CONTEMPORARY PSYCHIATRY
por: Nilsson, Lars
Publicado: (2020) -
T86. RELEVANCE OF CANNABIS USE AS A PREDICTOR OF CLINICAL OUTCOME IN FIRST-EPISODE SCHIZOPHRENIA SPECTRUM DISORDER PATIENTS OVER 24 MONTHS OF TREATMENT
por: Scheffler, Frederika, et al.
Publicado: (2020)